ArticleFrontiers in medicine2025
Assessing the relationship between gout and the risk of cataract in community-dwelling older adults: mediation and moderation analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to assess whether gout is a risk for cataract and identify important factors contributing to the association. Methods: A total of 381,402 individuals from the UK Biobank were enrolled at baseline (2006-2010). Cataract was ascertained using hospital inpatient and self-reported data until early 2021. Gout was determined by ICD-9, ICD-10, self-report, and medication at baseline. The Cox regression model was used to estimate the hazard ratio (HR) and 95% confidence intervals (CIs) for the risk of cataract. Results: The risk of cataract was significantly increased in patients with gout (HR, 1.69; 95% CI, 1.48-1.94; p < 0.001), and this association was attenuated but remained significant after additional adjusting for other covariates (HR, 1.14; 95% CI, 1.04-1.26; p = 0.006). In addition, we observed a significant interaction effect between gout and glucocorticoids (GCC) use for senile cataract (p = 0.04). In the sensitivity analysis, we stratified the population by sex, diabetes mellitus (DM), and GCC use. We noticed that gout remains a risk factor for cataract in both sexes and in patients with or without GCC use. Finally, we tested the mediation effect of GCC; we observed that 2.4% of the effect between gout and cataract and 3% of the effect between gout and senile cataract was mediated by GCC use. Conclusion: This cohort study found that gout was an independent risk factor for cataract, with a significant impact on senile cataract. GCC use modified the effect of gout on the development of senile cataract (interaction effect), thus prescribing GCC to patients with gout should be actively monitored for cataract development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.